Global Gene Modifying Immunotherapy for Blood Cancer Market Growth (Status and Outlook) 2022-2028

January 2021 | 85 pages | ID: GCC6014E9019EN
LP Information

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

As the global economy mends, the 2021 growth of Gene Modifying Immunotherapy for Blood Cancer will have significant change from previous year. According to our (LP Information) latest study, the global Gene Modifying Immunotherapy for Blood Cancer market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global Gene Modifying Immunotherapy for Blood Cancer market size will reach USD million in 2028, growing at a CAGR of % over the analysis period.

The United States Gene Modifying Immunotherapy for Blood Cancer market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Gene Modifying Immunotherapy for Blood Cancer market, reaching US$ million by the year 2028. As for the Europe Gene Modifying Immunotherapy for Blood Cancer landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.

Global main Gene Modifying Immunotherapy for Blood Cancer players cover Novartis, Kite Pharma, Juno Therapeutics, and Cellectis, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.

This report presents a comprehensive overview, market shares, and growth opportunities of Gene Modifying Immunotherapy for Blood Cancer market by product type, application, key players and key regions and countries.

Segmentation by type: breakdown data from 2017 to 2022 in Section 2.3; and forecast to 2028 in section 10.7.

• CAR T-cell Therapy
• TCR T-cell Therapy

Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 10.8.

• Acute Lymphocytic Leukemia
• Chronic Lymphocytic Leukemia
• B Cell Lymphoma
• Multiple Myeloma
• Other

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report: Breakdown data in in Chapter 3.

• Novartis
• Kite Pharma
• Juno Therapeutics
• Cellectis
• Ziopharm Oncology
• Celyad
• Bluebird Bio
• Bellicum Pharmaceuticals
• Mustang Bio

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Gene Modifying Immunotherapy for Blood Cancer Market Size 2017-2028
  2.1.2 Gene Modifying Immunotherapy for Blood Cancer Market Size CAGR by Region 2017 VS 2022 VS 2028
2.2 Gene Modifying Immunotherapy for Blood Cancer Segment by Type
  2.2.1 CAR T-cell Therapy
  2.2.2 TCR T-cell Therapy
2.3 Gene Modifying Immunotherapy for Blood Cancer Market Size by Type
  2.3.1 Gene Modifying Immunotherapy for Blood Cancer Market Size CAGR by Type (2017 VS 2022 VS 2028)
  2.3.2 Global Gene Modifying Immunotherapy for Blood Cancer Market Size Market Share by Type (2017-2022)
2.4 Gene Modifying Immunotherapy for Blood Cancer Segment by Application
  2.4.1 Acute Lymphocytic Leukemia
  2.4.2 Chronic Lymphocytic Leukemia
  2.4.3 B Cell Lymphoma
  2.4.4 Multiple Myeloma
  2.4.5 Other
2.5 Gene Modifying Immunotherapy for Blood Cancer Market Size by Application
  2.5.1 Gene Modifying Immunotherapy for Blood Cancer Market Size CAGR by Application (2017 VS 2022 VS 2028)
  2.5.2 Global Gene Modifying Immunotherapy for Blood Cancer Market Size Market Share by Application (2017-2022)

3 GENE MODIFYING IMMUNOTHERAPY FOR BLOOD CANCER MARKET SIZE BY PLAYER

3.1 Gene Modifying Immunotherapy for Blood Cancer Market Size Market Share by Players
  3.1.1 Global Gene Modifying Immunotherapy for Blood Cancer Revenue by Players (2020-2022)
  3.1.2 Global Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share by Players (2020-2022)
3.2 Global Gene Modifying Immunotherapy for Blood Cancer Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
  3.3.1 Competition Landscape Analysis
  3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion

4 GENE MODIFYING IMMUNOTHERAPY FOR BLOOD CANCER BY REGIONS

4.1 Gene Modifying Immunotherapy for Blood Cancer Market Size by Regions (2017-2022)
4.2 Americas Gene Modifying Immunotherapy for Blood Cancer Market Size Growth (2017-2022)
4.3 APAC Gene Modifying Immunotherapy for Blood Cancer Market Size Growth (2017-2022)
4.4 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size Growth (2017-2022)
4.5 Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Size Growth (2017-2022)

5 AMERICAS

5.1 Americas Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2017-2022)
5.2 Americas Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2017-2022)
5.3 Americas Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2017-2022)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Gene Modifying Immunotherapy for Blood Cancer Market Size by Region (2017-2022)
6.2 APAC Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2017-2022)
6.3 APAC Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2017-2022)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia

7 EUROPE

7.1 Europe Gene Modifying Immunotherapy for Blood Cancer by Country (2017-2022)
7.2 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2017-2022)
7.3 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2017-2022)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer by Region (2017-2022)
8.2 Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2017-2022)
8.3 Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2017-2022)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 GLOBAL GENE MODIFYING IMMUNOTHERAPY FOR BLOOD CANCER MARKET FORECAST

10.1 Global Gene Modifying Immunotherapy for Blood Cancer Forecast by Regions (2023-2028)
  10.1.1 Global Gene Modifying Immunotherapy for Blood Cancer Forecast by Regions (2023-2028)
  10.1.2 Americas Gene Modifying Immunotherapy for Blood Cancer Forecast
  10.1.3 APAC Gene Modifying Immunotherapy for Blood Cancer Forecast
  10.1.4 Europe Gene Modifying Immunotherapy for Blood Cancer Forecast
  10.1.5 Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Forecast
10.2 Americas Gene Modifying Immunotherapy for Blood Cancer Forecast by Country (2023-2028)
  10.2.1 United States Gene Modifying Immunotherapy for Blood Cancer Market Forecast
  10.2.2 Canada Gene Modifying Immunotherapy for Blood Cancer Market Forecast
  10.2.3 Mexico Gene Modifying Immunotherapy for Blood Cancer Market Forecast
  10.2.4 Brazil Gene Modifying Immunotherapy for Blood Cancer Market Forecast
10.3 APAC Gene Modifying Immunotherapy for Blood Cancer Forecast by Region (2023-2028)
  10.3.1 China Gene Modifying Immunotherapy for Blood Cancer Market Forecast
  10.3.2 Japan Gene Modifying Immunotherapy for Blood Cancer Market Forecast
  10.3.3 Korea Gene Modifying Immunotherapy for Blood Cancer Market Forecast
  10.3.4 Southeast Asia Gene Modifying Immunotherapy for Blood Cancer Market Forecast
  10.3.5 India Gene Modifying Immunotherapy for Blood Cancer Market Forecast
  10.3.6 Australia Gene Modifying Immunotherapy for Blood Cancer Market Forecast
10.4 Europe Gene Modifying Immunotherapy for Blood Cancer Forecast by Country (2023-2028)
  10.4.1 Germany Gene Modifying Immunotherapy for Blood Cancer Market Forecast
  10.4.2 France Gene Modifying Immunotherapy for Blood Cancer Market Forecast
  10.4.3 UK Gene Modifying Immunotherapy for Blood Cancer Market Forecast
  10.4.4 Italy Gene Modifying Immunotherapy for Blood Cancer Market Forecast
  10.4.5 Russia Gene Modifying Immunotherapy for Blood Cancer Market Forecast
10.5 Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Forecast by Region (2023-2028)
  10.5.1 Egypt Gene Modifying Immunotherapy for Blood Cancer Market Forecast
  10.5.2 South Africa Gene Modifying Immunotherapy for Blood Cancer Market Forecast
  10.5.3 Israel Gene Modifying Immunotherapy for Blood Cancer Market Forecast
  10.5.4 Turkey Gene Modifying Immunotherapy for Blood Cancer Market Forecast
  10.5.5 GCC Countries Gene Modifying Immunotherapy for Blood Cancer Market Forecast
10.6 Global Gene Modifying Immunotherapy for Blood Cancer Forecast by Type (2023-2028)
10.7 Global Gene Modifying Immunotherapy for Blood Cancer Forecast by Application (2023-2028)

11 KEY PLAYERS ANALYSIS

11.1 Novartis
  11.1.1 Novartis Company Information
  11.1.2 Novartis Gene Modifying Immunotherapy for Blood Cancer Product Offered
  11.1.3 Novartis Gene Modifying Immunotherapy for Blood Cancer Revenue, Gross Margin and Market Share (2020-2022)
  11.1.4 Novartis Main Business Overview
  11.1.5 Novartis Latest Developments
11.2 Kite Pharma
  11.2.1 Kite Pharma Company Information
  11.2.2 Kite Pharma Gene Modifying Immunotherapy for Blood Cancer Product Offered
  11.2.3 Kite Pharma Gene Modifying Immunotherapy for Blood Cancer Revenue, Gross Margin and Market Share (2020-2022)
  11.2.4 Kite Pharma Main Business Overview
  11.2.5 Kite Pharma Latest Developments
11.3 Juno Therapeutics
  11.3.1 Juno Therapeutics Company Information
  11.3.2 Juno Therapeutics Gene Modifying Immunotherapy for Blood Cancer Product Offered
  11.3.3 Juno Therapeutics Gene Modifying Immunotherapy for Blood Cancer Revenue, Gross Margin and Market Share (2020-2022)
  11.3.4 Juno Therapeutics Main Business Overview
  11.3.5 Juno Therapeutics Latest Developments
11.4 Cellectis
  11.4.1 Cellectis Company Information
  11.4.2 Cellectis Gene Modifying Immunotherapy for Blood Cancer Product Offered
  11.4.3 Cellectis Gene Modifying Immunotherapy for Blood Cancer Revenue, Gross Margin and Market Share (2020-2022)
  11.4.4 Cellectis Main Business Overview
  11.4.5 Cellectis Latest Developments
11.5 Ziopharm Oncology
  11.5.1 Ziopharm Oncology Company Information
  11.5.2 Ziopharm Oncology Gene Modifying Immunotherapy for Blood Cancer Product Offered
  11.5.3 Ziopharm Oncology Gene Modifying Immunotherapy for Blood Cancer Revenue, Gross Margin and Market Share (2020-2022)
  11.5.4 Ziopharm Oncology Main Business Overview
  11.5.5 Ziopharm Oncology Latest Developments
11.6 Celyad
  11.6.1 Celyad Company Information
  11.6.2 Celyad Gene Modifying Immunotherapy for Blood Cancer Product Offered
  11.6.3 Celyad Gene Modifying Immunotherapy for Blood Cancer Revenue, Gross Margin and Market Share (2020-2022)
  11.6.4 Celyad Main Business Overview
  11.6.5 Celyad Latest Developments
11.7 Bluebird Bio
  11.7.1 Bluebird Bio Company Information
  11.7.2 Bluebird Bio Gene Modifying Immunotherapy for Blood Cancer Product Offered
  11.7.3 Bluebird Bio Gene Modifying Immunotherapy for Blood Cancer Revenue, Gross Margin and Market Share (2020-2022)
  11.7.4 Bluebird Bio Main Business Overview
  11.7.5 Bluebird Bio Latest Developments
11.8 Bellicum Pharmaceuticals
  11.8.1 Bellicum Pharmaceuticals Company Information
  11.8.2 Bellicum Pharmaceuticals Gene Modifying Immunotherapy for Blood Cancer Product Offered
  11.8.3 Bellicum Pharmaceuticals Gene Modifying Immunotherapy for Blood Cancer Revenue, Gross Margin and Market Share (2020-2022)
  11.8.4 Bellicum Pharmaceuticals Main Business Overview
  11.8.5 Bellicum Pharmaceuticals Latest Developments
11.9 Mustang Bio
  11.9.1 Mustang Bio Company Information
  11.9.2 Mustang Bio Gene Modifying Immunotherapy for Blood Cancer Product Offered
  11.9.3 Mustang Bio Gene Modifying Immunotherapy for Blood Cancer Revenue, Gross Margin and Market Share (2020-2022)
  11.9.4 Mustang Bio Main Business Overview
  11.9.5 Mustang Bio Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Gene Modifying Immunotherapy for Blood Cancer Market Size CAGR by Region (2017 VS 2022 VS 2028) & ($ Millions)
Table 2. Major Players of CAR T-cell Therapy
Table 3. Major Players of TCR T-cell Therapy
Table 4. Gene Modifying Immunotherapy for Blood Cancer Market Size CAGR by Type (2017 VS 2022 VS 2028) & ($ Millions)
Table 5. Global Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2017-2022) & ($ Millions)
Table 6. Global Gene Modifying Immunotherapy for Blood Cancer Market Size Market Share by Type (2017-2022)
Table 7. Gene Modifying Immunotherapy for Blood Cancer Market Size CAGR by Application (2017 VS 2022 VS 2028) & ($ Millions)
Table 8. Global Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2017-2022) & ($ Millions)
Table 9. Global Gene Modifying Immunotherapy for Blood Cancer Market Size Market Share by Application (2017-2022)
Table 10. Global Gene Modifying Immunotherapy for Blood Cancer Revenue by Players (2020-2022) & ($ Millions)
Table 11. Global Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share by Player (2020-2022)
Table 12. Gene Modifying Immunotherapy for Blood Cancer Key Players Head office and Products Offered
Table 13. Gene Modifying Immunotherapy for Blood Cancer Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 14. New Products and Potential Entrants
Table 15. Mergers & Acquisitions, Expansion
Table 16. Global Gene Modifying Immunotherapy for Blood Cancer Market Size by Regions 2017-2022 & ($ Millions)
Table 17. Global Gene Modifying Immunotherapy for Blood Cancer Market Size Market Share by Regions (2017-2022)
Table 18. Americas Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2017-2022) & ($ Millions)
Table 19. Americas Gene Modifying Immunotherapy for Blood Cancer Market Size Market Share by Country (2017-2022)
Table 20. Americas Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2017-2022) & ($ Millions)
Table 21. Americas Gene Modifying Immunotherapy for Blood Cancer Market Size Market Share by Type (2017-2022)
Table 22. Americas Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2017-2022) & ($ Millions)
Table 23. Americas Gene Modifying Immunotherapy for Blood Cancer Market Size Market Share by Application (2017-2022)
Table 24. APAC Gene Modifying Immunotherapy for Blood Cancer Market Size by Region (2017-2022) & ($ Millions)
Table 25. APAC Gene Modifying Immunotherapy for Blood Cancer Market Size Market Share by Region (2017-2022)
Table 26. APAC Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2017-2022) & ($ Millions)
Table 27. APAC Gene Modifying Immunotherapy for Blood Cancer Market Size Market Share by Type (2017-2022)
Table 28. APAC Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2017-2022) & ($ Millions)
Table 29. APAC Gene Modifying Immunotherapy for Blood Cancer Market Size Market Share by Application (2017-2022)
Table 30. Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2017-2022) & ($ Millions)
Table 31. Europe Gene Modifying Immunotherapy for Blood Cancer Market Size Market Share by Country (2017-2022)
Table 32. Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2017-2022) & ($ Millions)
Table 33. Europe Gene Modifying Immunotherapy for Blood Cancer Market Size Market Share by Type (2017-2022)
Table 34. Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2017-2022) & ($ Millions)
Table 35. Europe Gene Modifying Immunotherapy for Blood Cancer Market Size Market Share by Application (2017-2022)
Table 36. Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Size by Region (2017-2022) & ($ Millions)
Table 37. Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Size Market Share by Region (2017-2022)
Table 38. Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2017-2022) & ($ Millions)
Table 39. Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Size Market Share by Type (2017-2022)
Table 40. Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2017-2022) & ($ Millions)
Table 41. Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Size Market Share by Application (2017-2022)
Table 42. Key Market Drivers & Growth Opportunities of Gene Modifying Immunotherapy for Blood Cancer
Table 43. Key Market Challenges & Risks of Gene Modifying Immunotherapy for Blood Cancer
Table 44. Key Industry Trends of Gene Modifying Immunotherapy for Blood Cancer
Table 45. Global Gene Modifying Immunotherapy for Blood Cancer Market Size Forecast by Regions (2023-2028) & ($ Millions)
Table 46. Global Gene Modifying Immunotherapy for Blood Cancer Market Size Market Share Forecast by Regions (2023-2028)
Table 47. Global Gene Modifying Immunotherapy for Blood Cancer Market Size Forecast by Type (2023-2028) & ($ Millions)
Table 48. Global Gene Modifying Immunotherapy for Blood Cancer Market Size Market Share Forecast by Type (2023-2028)
Table 49. Global Gene Modifying Immunotherapy for Blood Cancer Market Size Forecast by Application (2023-2028) & ($ Millions)
Table 50. Global Gene Modifying Immunotherapy for Blood Cancer Market Size Market Share Forecast by Application (2023-2028)
Table 51. Novartis Details, Company Type, Gene Modifying Immunotherapy for Blood Cancer Area Served and Its Competitors
Table 52. Novartis Gene Modifying Immunotherapy for Blood Cancer Product Offered
Table 53. Novartis Gene Modifying Immunotherapy for Blood Cancer Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 54. Novartis Main Business
Table 55. Novartis Latest Developments
Table 56. Kite Pharma Details, Company Type, Gene Modifying Immunotherapy for Blood Cancer Area Served and Its Competitors
Table 57. Kite Pharma Gene Modifying Immunotherapy for Blood Cancer Product Offered
Table 58. Kite Pharma Main Business
Table 59. Kite Pharma Gene Modifying Immunotherapy for Blood Cancer Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 60. Kite Pharma Latest Developments
Table 61. Juno Therapeutics Details, Company Type, Gene Modifying Immunotherapy for Blood Cancer Area Served and Its Competitors
Table 62. Juno Therapeutics Gene Modifying Immunotherapy for Blood Cancer Product Offered
Table 63. Juno Therapeutics Main Business
Table 64. Juno Therapeutics Gene Modifying Immunotherapy for Blood Cancer Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 65. Juno Therapeutics Latest Developments
Table 66. Cellectis Details, Company Type, Gene Modifying Immunotherapy for Blood Cancer Area Served and Its Competitors
Table 67. Cellectis Gene Modifying Immunotherapy for Blood Cancer Product Offered
Table 68. Cellectis Main Business
Table 69. Cellectis Gene Modifying Immunotherapy for Blood Cancer Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 70. Cellectis Latest Developments
Table 71. Ziopharm Oncology Details, Company Type, Gene Modifying Immunotherapy for Blood Cancer Area Served and Its Competitors
Table 72. Ziopharm Oncology Gene Modifying Immunotherapy for Blood Cancer Product Offered
Table 73. Ziopharm Oncology Main Business
Table 74. Ziopharm Oncology Gene Modifying Immunotherapy for Blood Cancer Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 75. Ziopharm Oncology Latest Developments
Table 76. Celyad Details, Company Type, Gene Modifying Immunotherapy for Blood Cancer Area Served and Its Competitors
Table 77. Celyad Gene Modifying Immunotherapy for Blood Cancer Product Offered
Table 78. Celyad Main Business
Table 79. Celyad Gene Modifying Immunotherapy for Blood Cancer Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 80. Celyad Latest Developments
Table 81. Bluebird Bio Details, Company Type, Gene Modifying Immunotherapy for Blood Cancer Area Served and Its Competitors
Table 82. Bluebird Bio Gene Modifying Immunotherapy for Blood Cancer Product Offered
Table 83. Bluebird Bio Main Business
Table 84. Bluebird Bio Gene Modifying Immunotherapy for Blood Cancer Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 85. Bluebird Bio Latest Developments
Table 86. Bellicum Pharmaceuticals Details, Company Type, Gene Modifying Immunotherapy for Blood Cancer Area Served and Its Competitors
Table 87. Bellicum Pharmaceuticals Gene Modifying Immunotherapy for Blood Cancer Product Offered
Table 88. Bellicum Pharmaceuticals Main Business
Table 89. Bellicum Pharmaceuticals Gene Modifying Immunotherapy for Blood Cancer Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 90. Bellicum Pharmaceuticals Latest Developments
Table 91. Mustang Bio Details, Company Type, Gene Modifying Immunotherapy for Blood Cancer Area Served and Its Competitors
Table 92. Mustang Bio Gene Modifying Immunotherapy for Blood Cancer Product Offered
Table 93. Mustang Bio Main Business
Table 94. Mustang Bio Gene Modifying Immunotherapy for Blood Cancer Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 95. Mustang Bio Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Gene Modifying Immunotherapy for Blood Cancer Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Gene Modifying Immunotherapy for Blood Cancer Market Size Growth Rate 2017-2028 ($ Millions)
Figure 6. Global Gene Modifying Immunotherapy for Blood Cancer Market Size Market Share by Type in 2021
Figure 7. Gene Modifying Immunotherapy for Blood Cancer in Acute Lymphocytic Leukemia
Figure 8. Global Gene Modifying Immunotherapy for Blood Cancer Market: Acute Lymphocytic Leukemia (2017-2022) & ($ Millions)
Figure 9. Gene Modifying Immunotherapy for Blood Cancer in Chronic Lymphocytic Leukemia
Figure 10. Global Gene Modifying Immunotherapy for Blood Cancer Market: Chronic Lymphocytic Leukemia (2017-2022) & ($ Millions)
Figure 11. Gene Modifying Immunotherapy for Blood Cancer in B Cell Lymphoma
Figure 12. Global Gene Modifying Immunotherapy for Blood Cancer Market: B Cell Lymphoma (2017-2022) & ($ Millions)
Figure 13. Gene Modifying Immunotherapy for Blood Cancer in Multiple Myeloma
Figure 14. Global Gene Modifying Immunotherapy for Blood Cancer Market: Multiple Myeloma (2017-2022) & ($ Millions)
Figure 15. Gene Modifying Immunotherapy for Blood Cancer in Other
Figure 16. Global Gene Modifying Immunotherapy for Blood Cancer Market: Other (2017-2022) & ($ Millions)
Figure 17. Global Gene Modifying Immunotherapy for Blood Cancer Market Size Market Share by Application in 2021
Figure 18. Global Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share by Player in 2021
Figure 19. Global Gene Modifying Immunotherapy for Blood Cancer Market Size Market Share by Regions (2017-2022)
Figure 20. Americas Gene Modifying Immunotherapy for Blood Cancer Market Size 2017-2022 ($ Millions)
Figure 21. APAC Gene Modifying Immunotherapy for Blood Cancer Market Size 2017-2022 ($ Millions)
Figure 22. Europe Gene Modifying Immunotherapy for Blood Cancer Market Size 2017-2022 ($ Millions)
Figure 23. Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Size 2017-2022 ($ Millions)
Figure 24. Americas Gene Modifying Immunotherapy for Blood Cancer Value Market Share by Country in 2021
Figure 25. Americas Gene Modifying Immunotherapy for Blood Cancer Consumption Market Share by Type in 2021
Figure 26. Americas Gene Modifying Immunotherapy for Blood Cancer Market Size Market Share by Application in 2021
Figure 27. United States Gene Modifying Immunotherapy for Blood Cancer Market Size Growth 2017-2022 ($ Millions)
Figure 28. Canada Gene Modifying Immunotherapy for Blood Cancer Market Size Growth 2017-2022 ($ Millions)
Figure 29. Mexico Gene Modifying Immunotherapy for Blood Cancer Market Size Growth 2017-2022 ($ Millions)
Figure 30. Brazil Gene Modifying Immunotherapy for Blood Cancer Market Size Growth 2017-2022 ($ Millions)
Figure 31. APAC Gene Modifying Immunotherapy for Blood Cancer Market Size Market Share by Region in 2021
Figure 32. APAC Gene Modifying Immunotherapy for Blood Cancer Market Size Market Share by Application in 2021
Figure 33. China Gene Modifying Immunotherapy for Blood Cancer Market Size Growth 2017-2022 ($ Millions)
Figure 34. Japan Gene Modifying Immunotherapy for Blood Cancer Market Size Growth 2017-2022 ($ Millions)
Figure 35. Korea Gene Modifying Immunotherapy for Blood Cancer Market Size Growth 2017-2022 ($ Millions)
Figure 36. Southeast Asia Gene Modifying Immunotherapy for Blood Cancer Market Size Growth 2017-2022 ($ Millions)
Figure 37. India Gene Modifying Immunotherapy for Blood Cancer Market Size Growth 2017-2022 ($ Millions)
Figure 38. Australia Gene Modifying Immunotherapy for Blood Cancer Market Size Growth 2017-2022 ($ Millions)
Figure 39. Europe Gene Modifying Immunotherapy for Blood Cancer Market Size Market Share by Country in 2021
Figure 40. Europe Gene Modifying Immunotherapy for Blood Cancer Market Size Market Share by Type in 2021
Figure 41. Europe Gene Modifying Immunotherapy for Blood Cancer Market Size Market Share by Application in 2021
Figure 42. Germany Gene Modifying Immunotherapy for Blood Cancer Market Size Growth 2017-2022 ($ Millions)
Figure 43. France Gene Modifying Immunotherapy for Blood Cancer Market Size Growth 2017-2022 ($ Millions)
Figure 44. UK Gene Modifying Immunotherapy for Blood Cancer Market Size Growth 2017-2022 ($ Millions)
Figure 45. Italy Gene Modifying Immunotherapy for Blood Cancer Market Size Growth 2017-2022 ($ Millions)
Figure 46. Russia Gene Modifying Immunotherapy for Blood Cancer Market Size Growth 2017-2022 ($ Millions)
Figure 47. Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Size Market Share by Region in 2021
Figure 48. Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Size Market Share by Type in 2021
Figure 49. Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Size Market Share by Application in 2021
Figure 50. Egypt Gene Modifying Immunotherapy for Blood Cancer Market Size Growth 2017-2022 ($ Millions)
Figure 51. South Africa Gene Modifying Immunotherapy for Blood Cancer Market Size Growth 2017-2022 ($ Millions)
Figure 52. Israel Gene Modifying Immunotherapy for Blood Cancer Market Size Growth 2017-2022 ($ Millions)
Figure 53. Turkey Gene Modifying Immunotherapy for Blood Cancer Market Size Growth 2017-2022 ($ Millions)
Figure 54. GCC Country Gene Modifying Immunotherapy for Blood Cancer Market Size Growth 2017-2022 ($ Millions)
Figure 55. Americas Gene Modifying Immunotherapy for Blood Cancer Market Size 2023-2028 ($ Millions)
Figure 56. APAC Gene Modifying Immunotherapy for Blood Cancer Market Size 2023-2028 ($ Millions)
Figure 57. Europe Gene Modifying Immunotherapy for Blood Cancer Market Size 2023-2028 ($ Millions)
Figure 58. Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Size 2023-2028 ($ Millions)
Figure 59. United States Gene Modifying Immunotherapy for Blood Cancer Market Size 2023-2028 ($ Millions)
Figure 60. Canada Gene Modifying Immunotherapy for Blood Cancer Market Size 2023-2028 ($ Millions)
Figure 61. Mexico Gene Modifying Immunotherapy for Blood Cancer Market Size 2023-2028 ($ Millions)
Figure 62. Brazil Gene Modifying Immunotherapy for Blood Cancer Market Size 2023-2028 ($ Millions)
Figure 63. China Gene Modifying Immunotherapy for Blood Cancer Market Size 2023-2028 ($ Millions)
Figure 64. Japan Gene Modifying Immunotherapy for Blood Cancer Market Size 2023-2028 ($ Millions)
Figure 65. Korea Gene Modifying Immunotherapy for Blood Cancer Market Size 2023-2028 ($ Millions)
Figure 66. Southeast Asia Gene Modifying Immunotherapy for Blood Cancer Market Size 2023-2028 ($ Millions)
Figure 67. India Gene Modifying Immunotherapy for Blood Cancer Market Size 2023-2028 ($ Millions)
Figure 68. Australia Gene Modifying Immunotherapy for Blood Cancer Market Size 2023-2028 ($ Millions)
Figure 69. Germany Gene Modifying Immunotherapy for Blood Cancer Market Size 2023-2028 ($ Millions)
Figure 70. France Gene Modifying Immunotherapy for Blood Cancer Market Size 2023-2028 ($ Millions)
Figure 71. UK Gene Modifying Immunotherapy for Blood Cancer Market Size 2023-2028 ($ Millions)
Figure 72. Italy Gene Modifying Immunotherapy for Blood Cancer Market Size 2023-2028 ($ Millions)
Figure 73. Russia Gene Modifying Immunotherapy for Blood Cancer Market Size 2023-2028 ($ Millions)
Figure 74. Spain Gene Modifying Immunotherapy for Blood Cancer Market Size 2023-2028 ($ Millions)
Figure 75. Egypt Gene Modifying Immunotherapy for Blood Cancer Market Size 2023-2028 ($ Millions)
Figure 76. South Africa Gene Modifying Immunotherapy for Blood Cancer Market Size 2023-2028 ($ Millions)
Figure 77. Israel Gene Modifying Immunotherapy for Blood Cancer Market Size 2023-2028 ($ Millions)
Figure 78. Turkey Gene Modifying Immunotherapy for Blood Cancer Market Size 2023-2028 ($ Millions)
Figure 79. GCC Countries Gene Modifying Immunotherapy for Blood Cancer Market Size 2023-2028 ($ Millions)